This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.
The goal of this program is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with CLL/SLL and MCL.
Upon completion of this activity, participants should be able to:
Plan BTKi-based therapeutic strategies for patients with CLL/SLL or MCL, taking into consideration global indications, regional/national expert recommendations, and recent practice-changing clinical trial results
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d'Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d'Hebron
Ana Marin-Niebla, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Gilead Kite, Janssen, Lilly, Takeda.
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; research support: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 05, 2023, through December 04, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.